View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 17, 2016

Pharming reports positive Phase II study results of RUCONEST to treat hereditary angioedema

Pharming Group has reported positive results from a Phase II clinical study of RUCONEST (recombinant C1 esterase inhibitor, 50IU / kg) for prophylaxis in patients suffering with hereditary angioedema (HAE).

Pharming Group has reported positive results from a Phase II clinical study of RUCONEST (recombinant C1 esterase inhibitor, 50 international units (IU) / kg) for prophylaxis in patients suffering with hereditary angioedema (HAE).

The study found that RUCONEST significantly reduced attack frequency for both the twice-weekly and once-weekly treatment regimens when compared with placebo.

The randomised, double-blind, placebo-controlled study enrolled 32 HAE patients deficient in C1 esterase inhibitor and a history of at least four attacks per month.

These patients received RUCONEST once and twice weekly and placebo in each of three four-week treatment periods in a cross-over design.

During the intent-to-treat analysis (ITT), the trial found a significant difference in the mean number of HAE attacks that patients experienced during treatment with both the twice-weekly (p-value <0.0001) and once-weekly (p-value =0.0004) RUCONEST regimen as compared with placebo.

Patients on placebo had a mean of 7.2 attacks per four week treatment period, which was reduced to a mean of 2.7 attacks on RUCONEST twice weekly and a mean of 4.4 attacks on RUCONEST once-weekly.

"Combined with the excellent safety profile, this data supports further development of recombinant C1INH as a useful preventive therapy for HAE."

 
UCSD's US HAEA Angioedema Centre medicine and clinical director professor and co-prinicipal investigator for the study Marc Riedl said: “The results of this well-controlled prophylactic study demonstrate a clinically relevant reduction of HAE attack frequency and a high responder rate with the recombinant C1INH treatment.

“Combined with the excellent safety profile, this data supports further development of recombinant C1INH as a useful preventive therapy for HAE.”

A rarely occurring genetic disorder, HAE shows symptoms such as spontaneous and recurrent swellings of the skin in different part of the anatomy.

Ruconest is currently also being tested in a Phase II clinical trial to treat HAE in young children aged between two and 13 years.


Image: Swollen hand of patient suffering from HAE. Photo: courtesy of LucyHAE via Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena